We have located links that may give you full text access.
FDA approves radiopharmaceutical for metastatic prostate cancer.
Cancer Discovery 2013 July
The U.S. Food and Drug Administration approved radium-223 dichloride for treatment of men with metastatic castration-resistant prostate cancer that has spread to the bone.
Full text links
Related Resources
Get seemless 1-tap access through your institution/university
For the best experience, use the Read mobile app
All material on this website is protected by copyright, Copyright © 1994-2024 by WebMD LLC.
This website also contains material copyrighted by 3rd parties.
By using this service, you agree to our terms of use and privacy policy.
Your Privacy Choices
You can now claim free CME credits for this literature searchClaim now
Get seemless 1-tap access through your institution/university
For the best experience, use the Read mobile app